


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A tTGase inhibitor of the formula:



wherein R_i and R₂ are independently selected from H, alkyl, alkenyl, cycloalkyl, aryl, heteroalkyl, heteroaryl, alkoxy, alkylthio, arakyl, aralkenyl, halo, haloalkyl, haloalkoxy, heterocyclyl, and heterocyclalkyl groups, an amino acid, a peptide, a peptidomimetic, or a peptidic protecting group; wherein R₂ can additionally be selected from the group consisting of LPYPQPQLPY, LPFPQPQLPF-NH₂, LPYPQPQLP, LPYPQPQLPYQPQP, where X₂₋₁₅ is a peptide consisting of any 2-15 amino acid residues followed by a C-terminal proline; R₃ is selected from F, and Br; n is from 0 to 10; and X is selected from the group consisting of O and NH, other than acid benzyl ester.

2. (original) The inhibitor of Claim 1, wherein R_i is selected from the group consisting of BnO, Me, Cbz, Fmoc, Boc, PQP, PQPQLPYPQP, QLQPFQP, LQLQPFQPPLPYPQP, where X₂₋₁₅ is a peptide consisting of any 2-15 amino acid residues followed by a N-terminal proline.


3. (original) The inhibitor of Claim 1, wherein R₂ is selected from the group consisting of hydroxy-phenyl)-methyl, OMe, OtBu, LPY, LPF-NH₂.

4. (original) The inhibitor of Claim 1, wherein is Br.

5. (original) The inhibitor of Claim 1, wherein said tTGase inhibitor is selected from the group consisting of: {(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2-phenyl-ethyl}-carbamic acid benzyl ester; 5-dihydro- isoxazol-5-ylmethyl)-carbamoyl]-butyric acid methyl ester; (S)-2-Benzyloxycarbonylamino- acid methyl ester; (S) -2- ester; acid benzyl ester; propionamide; acid benzyl ester; acid benzyl ester; [(S)-1-[(3-Bromo-4, 5- acid benzyl ester; carbamic acid benzyl ester;

acid benzyl ester; 5-dihydro- isoxazol-5-ylmethyl)-3-phenyl-urea ; chloro-5-trifluoromethyl-phenyl)-urea ; chloro-2-trifluoromethyl-phenyl)-urea ; fluoro-phenyl)-urea ; urea; {(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2-(4-fluoro-phenyl)- ethyl}-carbamic acid benzyl ester; {(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)- acid benzyl ester; 5- dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2- (1 H-indol-3-yl)-ethyl}-carbamic acid benzyl ester; {(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylamethyl)-carbamoyl]-2-(5-hydroxy-1H-indol-3-yl)- ethyl}-carbamic acid benzyl ester; acid pyridin-4-ylmethyl ester; {(S)-1-[(3- Bromo-4, 5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl}-carbamic acid ester; acid phenethyl ester; 5-dihydro- ester; {(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2-(4-hydroxy- [b] thiophen-2-ylmethyl ester; Bromo-4, carbamic acid 1, [b] thiophen-2-ylmethyl ester.

6. (original) A tTGase inhibitor of the formula:



where R2 and R3 are independently selected from H, a halo group, alkyl, aryl, and NO2.

7. (original) The tTGase inhibitor of Claim 11, wherein said inhibitor is selected from the group consisting of: 2,3-Dioxo-2, acid propylamide ; 2,3-Dioxo-2, 3-dihydro- 1 H-indole-5-sulfonic acid benzylamide ; (S)-1- (2, 3-Dioxo-2, 3-dihydro-1 H-indole-5-sulfonyl)- pyrrolidine-2-carboxylic acid methyl ester; (S)-2- (2, 3-Dioxo-2, 3-dihydro-1 H-indole-5- ; 3-dioxo-2,3- ; 2,3-dione ; 3-dione 8. A formulation for use in treatment of Celiac Sprue and/or dermatitis herpetiformis, comprising: an effective dose of the tTGase inhibitor according to any of claims 1-7 and a pharmaceutical acceptable excipient.

8. (currently amended) A formulation for use in treatment of Celiac Sprue and/or dermatitis herpetiformis, comprising:

an effective dose of the tTGase inhibitor according to any of ~~claims 1-7~~ claim 1 and a pharmaceutically acceptable excipient.

9. (original) A method of treating Celiac Sprue and/or dermatitis herpetiformis, the method comprising: administering to a patient an effective dose of a formulation according to Claim 8; wherein said tTGase inhibitor attenuates gluten toxicity in said patient 10. The method of Claim 9, wherein said formulation is administered with a glutenase.

11. (original) The method according to Claim 9, wherein said formulation is administered orally.

12. (original) The method according to Claim 9, wherein said formulation comprises an enteric coating.